8-K

0000950170-24-039484.txt : 20240401 0000950170-24-039484.hdr.sgml : 20240401 20240401170353 ACCESSION NUMBER: 0000950170-24-039484 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240401 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mind Medicine (MindMed) Inc. CENTRAL INDEX KEY: 0001813814 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40360 FILM NUMBER: 24810682 BUSINESS ADDRESS: STREET 1: ONE WORLD TRADE CENTER STREET 2: SUITE 8500 CITY: NEW YORK STATE: NY ZIP: 10007 BUSINESS PHONE: 212-220-6633 MAIL ADDRESS: STREET 1: ONE WORLD TRADE CENTER STREET 2: SUITE 8500 CITY: NEW YORK STATE: NY ZIP: 10007 8-K 1 mnmd-20240401.htm 8-K 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 01, 2024

   

Mind Medicine (MindMed) Inc.

(Exact name of Registrant as Specified in Its Charter)


British Columbia			001-40360	98-1582438
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)

One World Trade Center Suite 8500
New York, New York				10007
(Address of Principal Executive Offices)				(Zip Code)

    Registrant’s Telephone Number, Including Area Code: (212) 220-6633

   

    Not Applicable

   

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		MNMD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On April 1, 2024, Mind Medicine (MindMed) Inc. (the “Company”) issued a press release announcing that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. The common shares will continue to trade on Nasdaq under the symbol “MNMD.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Forward-Looking Statements

Certain statements in this Current Report on Form 8-K related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information contained in this Current Report on Form 8-K include, but are not limited to, statements with respect to the timing of the delisting of the Company’s common shares from Cboe Canada and the anticipated continued listing of the Company’s common shares on Nasdaq. There are numerous risks and uncertainties that could cause actual results timing and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including satisfaction of the customary closing conditions for the underwritten offering and the concurrent private placement. These forward-looking statements are based on our current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions, including the non-occurrence of the risks and uncertainties that are described in the filings made with the U.S. Securities and Exchange Commission and the applicable Canadian securities regulators or other events occurring outside of our normal course of business, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this Current Report on Form 8-K as a result of new information, future events, changes in expectations or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit		Description
99.1		Press Release, dated April 1, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Mind Medicine (MindMed) Inc.

Date:	April 1, 2024	By:	/s/ Robert Barrow
			Name: Robert Barrow Title: Chief Executive Officer

EX-99.1 2 mnmd-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

MindMed Announces Voluntary Delisting from Cboe Canada

All Common shares will remain listed on Nasdaq

NEW YORK, April 1, 2024 --(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed’s common shares will continue to be listed and tradable on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “MNMD” and Canadian shareholders can continue to trade their shares on Nasdaq.

The Company believes that the trading volume of its common shares on Cboe Canada no longer justifies the expense and administrative requirements associated with maintaining this dual listing. MindMed’s Nasdaq listing provides its shareholders with sufficient liquidity, as Nasdaq accounts for approximately 95% of its trading volume. The substantial savings in exchange fees, legal fees, and managerial time and effort to maintain a dual listing can be redirected to initiatives intended to generate shareholder value. The board of directors of the Company has approved the voluntary delisting from Cboe Canada. In accordance with the Cboe Canada Listing Manual, Cboe Canada does not require shareholder approval of the voluntary delisting of MindMed’s common shares, as an acceptable alternative market will exist for the common shares on the date of delisting.

Following delisting from Cboe Canada, MindMed’s shareholders can trade their common shares through their brokers on Nasdaq. As most brokers in Canada, including many discount and online brokers, have the ability to buy and sell securities listed on Nasdaq, MindMed’s Nasdaq listing will continue to provide shareholders with the same accessibility to trade the Company's common shares. Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade MindMed’s common shares on Nasdaq. MindMed will continue to be a reporting issuer under applicable securities laws in all provinces and territories of Canada following the delisting of the common shares from Cboe Canada.

For answers to frequently asked questions about the voluntary delisting, please visit the FAQ section of MindMed’s website at https://ir.mindmed.co/about/faq.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.

MindMed trades on Nasdaq under the symbol MNMD and currently trades on Cboe Canada (formerly known as the NEO Exchange) under the symbol MMED.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information contained in this news release include, but are not limited to, statements with respect to the timing of the delisting of the Company’s common shares from Cboe Canada, the Company’s anticipated benefits of delisting from Cboe Canada, such as improved liquidity for the common shares, the accessibility of and ability of shareholders to trade the Company's common shares on Nasdaq, and the anticipated continued listing of the Company's common shares on Nasdaq. There are numerous risks and uncertainties that could cause actual timing and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. These forward-looking statements are based on our current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions, including the non-occurrence of the risks and uncertainties that are described in the filings made with the U.S. Securities and Exchange Commission and the applicable Canadian securities regulators or other events occurring outside of our normal course of business, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.

For Media: media@mindmed.co

For investors: ir@mindmed.co

GRAPHIC 3 img158589805_0.jpg GRAPHIC begin 644 img158589805_0.jpg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end EX-101.SCH 4 mnmd-20240401.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Apr. 01, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 01, 2024
Entity Registrant Name	Mind Medicine (MindMed) Inc.
Entity Central Index Key	0001813814
Entity Emerging Growth Company	true
Entity File Number	001-40360
Entity Incorporation, State or Country Code	A1
Entity Tax Identification Number	98-1582438
Entity Address, Address Line One	One World Trade Center
Entity Address, Address Line Two	Suite 8500
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10007
City Area Code	(212)
Local Phone Number	220-6633
Entity Information, Former Legal or Registered Name	Not Applicable
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Ex Transition Period	false
Title of 12(b) Security	Common Shares
Trading Symbol	MNMD
Security Exchange Name	NASDAQ

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports mnmd-20240401.htm mnmd-20240401.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mnmd-20240401.htm": { "nsprefix": "mnmd", "nsuri": "http://www.mindmed.co/20240401", "dts": { "inline": { "local": [ "mnmd-20240401.htm" ] }, "schema": { "local": [ "mnmd-20240401.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_56b09d04-9b7a-49c0-897a-51b876a891ec", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "mnmd-20240401.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_56b09d04-9b7a-49c0-897a-51b876a891ec", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "mnmd-20240401.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.mindmed.co/20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-039484-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-039484-xbrl.zip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end XML 16 mnmd-20240401_htm.xml IDEA: XBRL DOCUMENT 0001813814 2024-04-01 2024-04-01 false 0001813814 8-K 2024-04-01 Mind Medicine (MindMed) Inc. A1 001-40360 98-1582438 One World Trade Center Suite 8500 New York NY 10007 (212) 220-6633 Not Applicable false false false false Common Shares MNMD NASDAQ true false